Executive interview – Orgenesis

Executive interview – Orgenesis

• Orgenesis is a vertically integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing.
• Through its Israeli subsidiary, Orgenesis Ltd, Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin producing cells (IPCs).
• Its Belgian subsidiary, MaSTherCell, is a global Contract Development and Manufacturing Organization (CDMO), through which Orgenesis is able to deliver optimised process industrialisation capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free